Advanced glycation end-products inhibition improves endothelial dysfunction in rheumatoid arthritis

International Journal of Rheumatic Diseases

Volumn 15, Issue 1, 2012, Pages 45-55

  Syngle, Ashit ^a,b   Vohra, Kanchan ^c   Garg, Nidhi ^c   Kaur, Ladbans ^d   Chand, Prem ^c  

^a Healing Touch City Clinic   (India)

^b Fortis Multispeciality Hospital   (India)

^c PUNJABI UNIVERSITY   (India)

^d Department of Radiology Prime Diagnostics ^*  (India)

Author keywords

Advanced glycation end products (AGEs) inhibitor; Endothelial dysfunction; Rheumatoid arthritis

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ANALGESIC, ANTIINFLAMMATORY, ANTIRHEUMATIC AND ANTIGOUT AGENTS; BENFOTIAMINE; C REACTIVE PROTEIN; DISEASE MODIFYING ANTIRHEUMATIC DRUG; GLYCERYL TRINITRATE; MECOBALAMIN; NITRITE; PYRIDOXAMINE; UNCLASSIFIED DRUG; VONDER;

ADULT; AGED; ARTICLE; BRACHIAL ARTERY; CLINICAL ARTICLE; DISEASE ACTIVITY; DRUG EFFICACY; DRUG SAFETY; ENDOTHELIAL DYSFUNCTION; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; HUMAN; MALE; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; VASODILATATION;

ADMINISTRATION, ORAL; ADULT; AGED; ANTI-INFLAMMATORY AGENTS; ARTHRITIS, RHEUMATOID; BIOLOGICAL MARKERS; BLOOD SEDIMENTATION; BRACHIAL ARTERY; C-REACTIVE PROTEIN; DISABILITY EVALUATION; ENDOTHELIUM, VASCULAR; FEMALE; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; INDIA; LINEAR MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PYRIDOXAMINE; QUESTIONNAIRES; SEVERITY OF ILLNESS INDEX; THIAMINE; TIME FACTORS; TREATMENT OUTCOME; VASODILATION; VITAMIN B 12; VITAMIN B COMPLEX; YOUNG ADULT;

EID: 84857058018     PISSN: 17561841     EISSN: 1756185X     Source Type: Journal    
DOI: 10.1111/j.1756-185X.2011.01679.x     Document Type: Article

References (48)

1. Syngle A (2006) Arthritis and its treatment. In: Rattan S, Kassem M (eds) Prevention and Treatment of Age Related Diseases, pp 105-32. Springer, Dordrecht, the Netherlands.
2. Hürlimann D, Forster A, Noll G, et al. (2002) Anti-tumour necrosis factor-alpha treatment improves endothelial function in patients with rheumatoid arthritis. Circulation106, 2184-7.
3. Gerli R, Goodson NJ (2005) Cardiovascular involvement in rheumatoid arthritis. Lupus14, 679-82.
4. Khan F (2010) Assessment of endothelial function as a marker of cardiovascular risk in patients with rheumatoid arthritis. Int J Rheum Dis13, 189-95.
5. Fatemah A, Sarah W, Emma W, Christopher E. (2010) Rheumatoid arthritis: etiopathogenesis, clinical features, diagnosis and evaluation. In: Syngle A, Deodhar SD (eds) Rheumatology Principles and Practice, pp 70-80. Jaypee, New Delhi, India.
6. Veerapen K, Mangat G, Watt I, et al. (1993) The expression of rheumatoid arthritis in Malaysian and British patients: a comparative study. Br J Rheumatol32, 541-5.
7. Bacon PA, Stevens RJ, Carruthers DM, et al. (2002) Accelerated atherogenesis in autoimmune rheumatic diseases. Autoimmun Rev1, 338-47.
8. Gonzalez-Juanatey C, Testa A, Garcia-Castelo A, et al. (2003) HLA-DRB1 status affects endothelial function in treated patients with rheumatoid arthritis. Am J Med114, 647-52.
9. Bilsborough W, Keen H, Taylor A, O'Driscoll GJ, Arnolda L, Green DJ (2006) Anti-tumour necrosis factor-alpha therapy over conventional therapy improves endothelial function in adults with rheumatoid arthritis. Rheumatol Int26, 1125-31.
10. Vaudo G, Marchesi S, Gerli R, et al. (2004) Endothelial dysfunction in young patients with rheumatoid arthritis and low disease activity. Ann Rheum Dis63, 31-5.
11. Dessein PH, Joffe BI, Singh S (2005) Biomarkers of endothelial dysfunction, cardiovascular risk factors and atherosclerosis in rheumatoid arthritis. Arthritis Res Ther7, R634-43.
12. Schmitt-Sody M, Metz P, Klose A, et al. (2007) In vivo interactions of platelets and leucocytes with the endothelium in murine antigen-induced arthritis: the role of P-selectin. Scand J Rheumatol36, 311-9.
13. Lipsky PE, Van der Heijde DM, St Clair EW, et al. (2000) Infliximab and methotrexate in treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med343, 1594-602.
14. Davignon J, Ganz P (2004) Role of endothelial dysfunction in atherosclerosis. Circulation109, III27-32.
15. Hofmann MA, Drury S, Hudson BI, et al. (2002) RAGE and arthritis: the G82S polymorphism amplifies the inflammatory response. Genes Immun3, 123-35.
16. Wautier JL, Schmidt AM (2004) Protein glycation: a firm link to endothelial cell dysfunction. Circ Res95, 233-8.
17. Voziyan PA, Hudson BG (2005) Pyridoxamine as a multifunctional pharmaceutical: targeting pathogenic glycation and oxidative damage. Cell Mol Life Sci62(15), 1671-81.
18. Hammes HP, Du X, Edelstein D, et al. (2003) Benfotiamine blocks three major pathways of hyperglycemic damage and prevents experimental diabetic retinopathy. Nat Med9, 294-9.
19. Berrone E, Beltramo E, Solimine C (2006) Regulation of intracellular glucose and polyol pathway by Thiamine and benfotiamine in vascular cells cultured in high glucose. J Biol Chem281, 9307-13.
20. Beltramo E, Berrone E, Buttiglieri S, Porta M (2004) Thiamine and benfotiamine prevents increase apoptosis in endothelial cells and pericytes cultured in highglucose. Diabetes Metab Res Rev20, 330-6.
21. Guuiliams TG (2004) Homocysteine-A risk factor for vascular disease: guidelines for the clinical practice. J Am Nutr Assoc7, 11-24.
22. Wheatley C (2007) Cobalamin in inflammation III - glutathionylcobalamin and Methylcobalamin/adenosylcobalamin coenzymes: the sword in the stone? How cobalamin may directly regulate the nitric oxide synthases. J Nutr Environ Med16(3-4), 212-26.
23. Xia L, Cregan AG, Berben LA, Brasch NE (2004) Studies on the formation of glutathionylcobalamin: any free intracellular aquacobalamin is likely to be rapidly and irreversibly converted to glutathionylcobalamin. Inorg Chem43, 6848-57.
24. Rachmilewitz D, Ligumsky M, Rachmilewitz B, et al. (1980) Transcobalamin II level in peripheral blood monocytes -a biochemical marker in inflammatory diseases of the bowel. Gastroenterology78, 43-6.
25. Dubnoff JW, Bartron E (1956) The effect of B12 on enzyme activity in E. coli mutant 113-3. Arch Biochem Biophys61, 99-110.
26. Hernanz A, Plaza A, Martin-Mola E, Miguel E (1999) Increased plasma levels of homocysteine and other thiol compounds in rheumatoid arthritis women. Clin Biochem32, 65-70.
27. Solomon LR (2006) Disorders of cobalamin (Vitamin B12) metabolism: emerging concepts in pathophysiology, diagnosis and treatment. Blood Rev21, 113-30.
28. Umesh CS, Sumitra S, Kota VR (2009) Prevention of Endotoxin-Induced Uveitis in Rats by Benfotiamine, a Lipophilic Analogue of Vitamin B1. Invest Ophthalmol Vis Sci50(5), 2276-82.
29. Stirban A, Negrean M, Stratmann B, et al. (2006) Benfotiamine prevents macro- and microvascular endothelial dysfunction and oxidative stress following a meal rich in advanced glycation end products in individuals with type 2 diabetes. Diabetes Care29, 2064-71.
30. Sastry KV, Moudgal RP, Mohan J, Tyagi JS, Rao GS (2002) Spectrophotometric determination of serum nitrite and nitrate by copper-cadmium alloy. Anal Biochem306, 79-82.
31. Wanchu A, Khullar M, Sud A, Bambrey P (1999) Nitric oxide production is increased in patients with inflammatory myositis. Nitric Oxide3, 454-8.
32. Himento M, Ishibashi T, Nakano S, et al. (2003) A practical procedure for achieving a steady state of NOx concentration in plasma: with special reference to NOx content of Japanese daily food. Tohoku J Exp Med199, 95-110.
33. Van Gestel AM, Li RK, Mickle DA, Stewart DJ (1996) Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Arthritis Rheum39, 34-40.
34. Kumar A, Malaviya AN, Pandhi A, Singh R (2002) Validation of an Indian version of the Health Assessment Questionnaire in patients with rheumatoid arthritis. Rheumatology (Oxford)41, 1457-9.
35. Munch G, Keis R, Wessels A, et al. (1997) Determination of advanced glycation end products in serum by fluorescence spectroscopy and competitive elisa. Eur J Clin Chem Clin Biochem35(9), 669-77.
36. Kirby A, Gebski V, Keech AC (2002) Determining the sample size in a clinical trial. Med J Aust177, 256-7.
37. Saowanee K, Monchand V, Oravan V, Kitti T, Mongkol V (2000) Levels of plasma lipid peroxide products and antioxidant status in rheumatoid arthritis. Immunology31, 335-7.
38. Shingu M, Nagai Y, Isayama T (1993) The effect of cytokines on metalloproteinase inhibitors (TIMP) & collagenase production by human chondrocytes and TIMP production by synovial cells & endothelial cells. Clin Exp Immunol1, 94.
39. Rodriguez-García J, Requena J, Rodríguez-Segade S (1998) Increased concentrations of serum pentosidine in rheumatoid arthritis. Clin Chem44, 250-5.
40. Peretz A, Siderova V, Neve J (2001) Selenium supplementation in rheumatoid arthritis investigated in a double blind, placebo-controlled trial. Scand J Rheumatol30, 208-12.
41. Susan J, Vojtech M, Lia C, et al. (2007) Advanced glycation endproduct crosslink breaker (alagebrium) improves endothelial function in patients with isolated systolic hypertension. J Hypertens25, 577-83.
42. Noyan G, John F, Balz F, et al. (1999) Long-term ascorbic acid administration reverses endothelial vasomotor dysfunction in patients with coronary artery disease. Circulation99, 3234-40.
43. Wållberg-Jonsson S, Caidahl K, Klintland N, Nyberg G, Rantapää-Dahlqvist S (2008) Increased arterial stiffness and indication of endothelial dysfunction in long-standing rheumatoid arthritis. Scand J Rheumatol37, 1-5.
44. Landmesser U, Dikalov S, Price SR, et al. (2003) Oxidation of tetrahydrobiopterin leads to uncoupling of endothelial cell nitric oxide synthase in hypertension. J Clin Invest111, 1201-9.
45. Ersoy Y, Ozerol E, Baysal O, et al. (2002) Serum nitrate and nitrite levels in patients with rheumatoid arthritis, ankylosing spondylitis, and osteoarthritis. Ann Rheum Dis61, 76-8.
46. Bots ML, Westerink J, Rabelink TJ, de Koning EJ (2005) Assessment of flow-mediated vasodilatation (FMD) of the brachial artery: effects of technical aspects of the FMD measurement on the FMD response. Eur Heart J26, 363-8.
47. Yki-Järvinen H, Bergholm R, Leirisalo-Repo M (2003) Increased inflammatory activity parallels increased basal nitric oxide production and blunted response to nitric oxide in vivo in rheumatoid arthritis. Ann Rheum Dis62, 630-4.
48. Vijaykumar D, Suresh K, Manoharan S (2005) Altered pattern of lipids in plasma and erythrocyte membranes of rheumatoid arthritis patients. Ind J Clin Biochem20, 52-5.